Amylin Advises All Shareholders to Vote Their Blue Proxy Card Today
May 26 2009 - 6:27PM
PR Newswire (US)
Amylin Urges Shareholders to Support the Company's Twelve Nominees
SAN DIEGO, May 26 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals,
Inc. (NASDAQ:AMLN) today reminded its shareholders to use their
BLUE proxy card to vote FOR all of Amylin's nominees, including its
two new independent Director nominees: Paul N. Clark and Paulo F.
Costa. Amylin urges shareholders to disregard any proxy cards
received from Carl Icahn and Eastbourne Capital Management, L.L.C.
Amylin's 2009 Annual Meeting of Stockholders is taking place
tomorrow, May 27, 2009. It is important that shareholders vote as
soon as possible to ensure that they benefit from the value
creation opportunity of exenatide once weekly, the Company's
investigational therapy that has the potential to transform the
treatment of type 2 diabetes. The Company asks that shareholders
please vote by telephone or Internet according to the instructions
on the BLUE proxy card, or by signing, dating and mailing the BLUE
proxy card. Even if shareholders have already voted using Icahn's
or Eastbourne's proxy card, they have the right to change their
vote simply by executing and submitting the BLUE proxy card, as
only the last dated proxy card will count. Voting by telephone or
Internet is more likely to ensure that shareholders' votes will be
counted. "We would like to again remind all Amylin shareholders to
vote," said James N. Wilson, Amylin's Lead Independent Director.
"Amylin's nominees are knowledgeable leaders who bring extensive
experience in biopharmaceuticals and diabetes as well as valuable
operational and marketing expertise. We are confident that our
nominees possess the qualifications to oversee the successful
execution of Amylin's stated strategy for creating value in 2009
and beyond. We would like to thank all the shareholders who have
expressed their support or have already voted for all twelve of
Amylin's nominees." As previously announced, Amylin's 2009 Annual
Meeting of Stockholders will be held at 8:30 a.m., Pacific Standard
Time, on Wednesday, May 27, 2009, at Amylin's offices located at
4575 Eastgate Mall, San Diego, CA 92121. Your Vote Is Important, No
Matter How Many Or How Few Shares You Own If you have questions
about how to vote your shares, or need additional assistance,
please contact the firm assisting us in the solicitation of
proxies: INNISFREE M&A INCORPORATED Stockholders Call
Toll-Free: (877) 717-3926 Banks and Brokers Call Collect: (212)
750-5833 IMPORTANT We urge you NOT to vote using any White or Gold
proxy card sent to you by Icahn or Eastbourne, as doing so will
revoke your vote on the BLUE proxy card. If you have already done
so, you have every legal right to change your vote by using the
enclosed BLUE proxy card to vote today--by telephone, by Internet,
or by signing, dating and returning the BLUE proxy card in the
postage-paid envelope provided. About Amylin Amylin Pharmaceuticals
is a biopharmaceutical company committed to improving lives through
the discovery, development and commercialization of innovative
medicines. Amylin has developed and gained approval for two
first-in-class medicines for diabetes, SYMLIN(R) (pramlintide
acetate) injection and BYETTA(R) (exenatide) injection. Amylin's
research and development activities leverage the Company's
expertise in metabolism to develop potential therapies to treat
diabetes and obesity. Amylin is headquartered in San Diego,
California. Further information on Amylin Pharmaceuticals is
available at http://www.amylin.com/. Forward Looking Statements
This press release contains forward-looking statements about
Amylin, which involve risks and uncertainties. Our actual results
could differ materially from those discussed herein due to a number
of risks and uncertainties, including risks that BYETTA, SYMLIN or
exenatide once weekly may be affected by competition, unexpected
new data, safety and technical issues, or manufacturing and supply
issues; risks that our financial results may fluctuate
significantly from period to period and may not meet market
expectations; risks that any financial guidance we provide may not
be accurate; risks that our clinical trials will not be completed
when planned, may not replicate previous results or achieve desired
end-points; risks that our preclinical studies may not be
predictive; risks that our NDAs for product candidates or sNDAs for
label expansion requests, such as the exenatide once weekly NDA
mentioned in this press release, may not be submitted timely or
receive FDA approval; risks that our expense reductions will not be
as large as we expect; risks that the restructured operations for
exenatide will not produce the results we expect; and other risks
inherent in the drug development and commercialization process.
Commercial and government reimbursement and pricing decisions and
the pace of market acceptance may also affect the potential for
BYETTA, SYMLIN or exenatide once weekly. These and additional risks
and uncertainties are described more fully in the Company's most
recently filed Form 10-K and Form 10-Q. Amylin disclaims any
obligation to update these forward-looking statements. Additional
Information and Where To Find It This press release may be deemed
to be solicitation material in respect of the matters to be
considered at the 2009 Annual Meeting of Stockholders. Amylin has
filed the definitive proxy statement with the Securities and
Exchange Commission ("SEC") on April 20, 2009. INVESTORS AND
SECURITYHOLDERS ARE URGED TO READ THE PROXY STATEMENT, THE BLUE
PROXY CARD AND ANY OTHER RELEVANT DOCUMENTS FILED OR THAT WILL BE
FILED WITH THE SEC BECAUSE THEY CONTAIN IMPORTANT INFORMATION.
Investors and securityholders may obtain the proxy statement and
other relevant documents free of charge at the SEC's Web site,
http://www.sec.gov/ or from Amylin Investor Relations at 9360 Towne
Centre Drive, San Diego, California 92121. Participants in
Solicitation Amylin and its directors and executive officers and
other members of management and employees may be deemed to be
participants in the solicitation of proxies in respect of the
matters to be considered at the 2009 Annual Meeting of
Stockholders. Information regarding the interests of Amylin's
directors and executive officers in the proxy contest is included
in Amylin's definitive proxy statement. CONTACTS: Alice Izzo
Executive Director, Corporate Affairs Amylin Pharmaceuticals, Inc.
(858) 642-7272 or Joele Frank / Jim Golden Joele Frank, Wilkinson
Brimmer Katcher (212) 355-4449 DATASOURCE: Amylin Pharmaceuticals,
Inc. CONTACT: Alice Izzo, Executive Director, Corporate Affairs of
Amylin Pharmaceuticals, Inc., +1-858-642-7272, ; or Joele Frank, or
Jim Golden, both of Joele Frank, Wilkinson Brimmer Katcher,
+1-212-355-4449 Web Site: http://www.amylin.com/
Copyright
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024